InvivoSciences
InvivoSciences, Inc. (IVS) is a precision medicine company that personalizes drug development using patient-derived and gene-edited human 3D engineered micro-heart tissue. Their platform integrates automation, tissue phenotyping assays, and computational biology (AI) to rapidly and cost-effectively identify the safety and efficacy profiles of treatments for specific patient groups before clinical trials. IVS's technology aims to reduce clinical trial failure rates, particularly for treatments causing arrhythmia and heart failure, and to develop patient-specific therapies. They have identified new drug repurposing pipelines for cardiac fibrosis in genetically defined heart failure and are expanding disease models for various genetic heart failures. The company's core competency lies in the automated mass production of patient-specific micro-heart tissue called NuHeart™, coupled with a high-throughput phenotypic assay platform.
InvivoSciences
InvivoSciences, Inc. (IVS) is a precision medicine company that personalizes drug development using patient-derived and gene-edited human 3D engineered micro-heart tissue. Their platform integrates automation, tissue phenotyping assays, and computational biology (AI) to rapidly and cost-effectively identify the safety and efficacy profiles of treatments for specific patient groups before clinical trials. IVS's technology aims to reduce clinical trial failure rates, particularly for treatments causing arrhythmia and heart failure, and to develop patient-specific therapies. They have identified new drug repurposing pipelines for cardiac fibrosis in genetically defined heart failure and are expanding disease models for various genetic heart failures. The company's core competency lies in the automated mass production of patient-specific micro-heart tissue called NuHeart™, coupled with a high-throughput phenotypic assay platform.